Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells

"* clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function."

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
collaborator

Changshu Frist People's Hospital

UNKNOWN

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

Affiliated Hospital of Jiangnan University

OTHER

collaborator

Jiangsu Province Hospital of Traditional Chinese Medicine

OTHER

collaborator

Jiangyin People's Hospital

OTHER

collaborator

Jingjiang People's Hospital

OTHER

collaborator

The Third People's Hospital of Kunshan

UNKNOWN

collaborator

Lianyungang Hospital Affiliated Bengbu Medical College

OTHER

collaborator

Suzhou Municipal Hospital

OTHER

collaborator

Zhangjiagang First People's Hospital

OTHER

collaborator

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Nanjing Medical University

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER